Biogenerics need a more rigorous approval process, FDA says

08/4/2011 | Reuters

Biosimilars require a regulatory pathway in which more data are analyzed and the "totality of evidence" is examined, FDA officials said in an article published in The New England Journal of Medicine. "Given the complex nature of biologics, it's unlikely that a 'one size fits all' systematic assessment of biosimilarity can be developed," agency officials said. The FDA plans to issue guidelines this year for seeking approval of such drugs.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX